R&D Immune mediation, B-cell depletion, and female leadership – ... In a new pharmaphorum podcast, Aoife Brennan, CEO of Climb Bio, discusses the treatment of immune-mediated diseases.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
Oncology On nuclear medicine and oncology, SHINE Technologies Greg Piefer, founder and CEO of SHINE Technologies, discusses nuclear medicine and the role of radiopharmaceuticals in oncology.
Digital Unicorns, AI, and the future of health: Highlights from HLTH... Deep Dive editor Eloise McLennan debriefs on the key themes, hot topics, and hallway conversations that shaped the HLTH event in Amsterdam.
Patients On patient-centric treatment decisions and the value of quan... Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, discusses the pressing need for quantitative methodologies.
R&D Maximising value by uniting the digital backbone: On a new N... Novo Nordisk and Veeva have entered into a new partnership for clinical development.
News BMS's Breyanzi is first CAR-T for marginal zone lymphoma Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
